Crossmark

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Crossref DOI link: https://doi.org/10.1186/s40425-018-0316-z

Published Online: 2018-01-23

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gong, Jun

Chehrazi-Raffle, Alexander

Reddi, Srikanth

Salgia, Ravi https://orcid.org/0000-0001-9643-7626
More Information

Article History

Received: 22 October 2017

Accepted: 9 January 2018

First Online: 23 January 2018

Ethics approval and consent to participate

: Not applicable

: Not applicable

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.